In an interview with SmartTRAK, Prof. Giuseppe Filardo, executive board member and second vice president of the International Cartilage Regeneration & Joint Preservation Society (ICRS), previews the 2026 ICRS Summit, emphasizing a shift toward joint preservation to delay invasive arthroplasty. He cautions against orthobiologic hype, clarifying that treatments like platelet-rich plasma (PRP) offer homeostatic relief rather than true tissue regeneration. The summit unites clinicians, researchers, and industry to evaluate preservation strategies and demand rigorous methodology prior to clinical adoption.
If you'd like to find out more, click on the following video (54:29 min). Interview topics, organized by timecode, are provided below. A link to download a complete transcript of the interview is also available below.
00:07 From pothole filling to joint preservation.
03:05 Industry as an ally.
04:33 Is the Regenerative Era really here?
10:50 Inside the RAND/UCLA Consensus.
24:50 Cortisone, hyaluronic acid or PRP?
29:46 The real enemy: metal in younger knees.
34:10 Synthetic implants as a bridge.
37:14 Intraosseous injections: A skeptic’s view.
45:51 What’s next? The months after surgery.
51:00 How do we measure success?
Interested in the 2026 ICRS Summit? Click the button below to download a complete transcript of SmartTRAK GM/Sr Analyst David Shepherd's exclusive interview with Prof. Giuseppe Filardo, executive board member and second VP of the International Cartilage Regeneration & Joint Preservation Society (ICRS).